

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TWI PHARMACEUTICALS, INC.
Petitioner,

v.

MERCK SERONO SA
Patent Owner.

Patent No. 8,377,903

Patent No. 7,713,947

Inter Partes Review IPR2023-00049

DECLARATION OF BENJAMIN M. GREENBERG, M.D.

TABLE OF CONTENTS

I.	QUALIFICATIONS AND BACKGROUND	8
A.	Education and Experience	8
B.	Bases for Opinions and Materials Considered	11
C.	Scope of Work	11
II.	SUMMARY OF OPINIONS	12
III.	PERSON OF ORDINARY SKILL IN THE ART	13
IV.	THE '947 PATENT (Ex. 1001)	14
A.	Overview	14
B.	The Challenged Claims of the '947 Patent	15
V.	THE '903 PATENT (Ex. 1002)	17
A.	Overview	17
B.	The Challenged Claims of the '903 Patent	18
VI.	CLAIM CONSTRUCTION	20
VII.	BACKGROUND AND STATE OF THE ART	21
A.	Multiple Sclerosis	21
B.	Underlying Causes of MS	24
C.	Multiple Sclerosis Therapies	25
D.	The Prior Art References	37
1.	Bodor WO '101 and Bodor '328	37
2.	Rice 2000	40
VIII.	OPINIONS ON GROUNDS OF UNPATENTABILITY	44
A.	Legal Standards	44
B.	Ground 1: Claims 36, 38–39, 41–48 of the '947 Patent, and claims 17, 19–20, and 22–29 of the '903 Patent are unpatentable Under 35 U.S.C. § 102 as Anticipated by Bodor	49
1.	Independent Claim 36 of the '947 Patent	50
a.	Limitation 1: Preamble: “A method of treating multiple sclerosis comprising the oral administration of a formulation comprising cladribine following the sequential steps below:”	50

b.	Limitation 2: “an induction period lasting from about 2 months to about 4 months wherein said formulation is orally administered and wherein the total dose of cladribine reached at the end of the induction period is from about 1.7 mg/kg to about 3.5 mg/kg” ..51	
c.	Limitation 3: “a cladribine-free period lasting from about 8 months to about 10 months, wherein no cladribine is administered” ..57	57
d.	Limitation 4: “a maintenance period lasting from about 2 months to about 4 months, wherein said formulation is orally administered and wherein the total dose of cladribine reached at the end of the maintenance period is about 1.7 mg/kg;” ..57	57
e.	Limitation 5: “a cladribine-free period wherein no cladribine is administered” ..64	64
2.	Dependent Claim 38 of the ’947 Patent: “method according to claim 36, wherein the induction period lasts about 2 months” ..65	65
3.	Dependent Claim 39 of the ’947 Patent: “method according to claim 36, wherein the total dose of cladribine reached at the end of the induction period is about 1.7 mg/kg” ..65	65
4.	Dependent Claim 41 of the ’947 Patent: “method according to claim 36, wherein the cladribine-free period (ii) lasts about 10 months” ..66	66
5.	Dependent Claim 42 of the ’947 Patent: “method according to claim 36, wherein the cladribine-free (iv) period lasts 10 months ..67	67
6.	Dependent Claim 43 of the ’947 Patent: “method according to claim 36, wherein the maintenance period lasts about 2 months” ..67	67
7.	Dependent Claim 44 of the ’947 Patent: “method according to claim 36, wherein the formulation is orally administered at a daily dose of 3 to 30 mg cladribine” ..68	68
8.	Dependent Claim 45 of the ’947 Patent: “method according to claim 36, wherein the formulation is orally administered at a daily dose of 10 mg cladribine” ..69	69
9.	Dependent Claim 46 of the ’947 Patent: “method according to claim 36, wherein the formulation is orally administered 1 to 7 days per month” ..69	69
10.	Dependent Claim 47 of the ’947 Patent: “method according to claim 36, wherein the steps (iii) to (iv) are repeated at least one or two times” ..70	70

11. Dependent Claim 48 of the '947 Patent: “method according to claim 36, wherein the formulation is administered in combination with interferon-beta”	71
12. Independent Claim 17 of the '903 Patent.....	71
13. Dependent Claim 19 of the '903 Patent: “method according to claim 17, wherein the induction period lasts about 2 months”	77
14. Dependent Claim 20 of the '903 Patent: “method according to claim 17, wherein the total dose of cladribine reached at the end of the induction period is about 1.7 mg/kg”	77
15. Dependent Claim 22 of the '903 Patent: “method according to claim 17, wherein the cladribine-free period (ii) lasts about 10 months”.....	79
16. Dependent Claim 23 of the '903 Patent: “method according to claim 17, wherein the cladribine-free (iv) period lasts 10 months”	79
17. Dependent Claim 24 of the '903 Patent: “method according to claim 17, wherein the maintenance period lasts about 2 months”	80
18. Dependent Claim 25 of the '903 Patent: “method according to claim 17, wherein the formulation is orally administered at a daily dose of 3 to 30mg”	81
19. Dependent Claim 26 of the '903 Patent: “method according to claim 17, wherein the formulation is orally administered at a daily dose of 10mg cladribine”	81
20. Dependent Claim 27 of the '903 Patent: “method according to claim 17, wherein the formulation is orally administered 1 to 7 days per month during the induction period”	82
21. Dependent Claim 28 of the '903 Patent: “method according to claim 17, wherein the steps (iii) to (iv) are repeated at least one or two times”	83
22. Dependent Claim 29 of the '903 Patent: “method according to claim 17, wherein the formulation is administered in combination with interferon-beta”	84
C. Ground 2: Claims 36, 38–39, 41–48 of the '947 Patent and claims 17, 19–20, and 22–29 of the '903 Patent are Unpatentable Under 35 U.S.C. § 103 Over Bodor.....	84
1. It would have been obvious to administer a total dosage amount of about 1.7 mg/kg per administration round	85

2.	It would have been obvious to repeat the same administration regimen after the cladribine-free period.....	87
3.	It would have been obvious to use Bodor’s oral cladribine dosage form and treatment regimen to treat relapsing-remitting and early secondary progressive multiple sclerosis.....	90
D.	Ground 3: Claims 36, 38–39, 41–48 of the ’947 Patent and claims 17, 19–20, and 22–29 of the ’903 Patent are Unpatentable Under 35 U.S.C. § 103(a) Over Bodor in view of Rice 2000.....	93
1.	Independent Claim 36 of the ’947 Patent.....	95
a.	Limitation 1: Preamble: “A method of treating multiple sclerosis comprising the oral administration of a formulation comprising cladribine following the sequential steps below:”.....	95
b.	Limitation 2: “an induction period lasting from about 2 months to about 4 months wherein said formulation is orally administered and wherein the total dose of cladribine reached at the end of the induction period is from about 1.7 mg/kg to about 3.5 mg/kg” ..	95
c.	Limitation 3: “a cladribine-free period lasting from about 8 months to about 10 months, wherein no cladribine is administered”	102
d.	Limitation 4: “a maintenance period lasting from about 2 months to about 4 months, wherein said formulation is orally administered and wherein the total dose of cladribine reached at the end of the maintenance period is about 1.7 mg/kg;”	102
e.	Limitation 5: “a cladribine-free period wherein no cladribine is administered”	105
2.	Dependent Claim 38 of the ’947 Patent: “method according to claim 36, wherein the induction period lasts about 2 months”	106
3.	Dependent Claim 39 of the ’947 Patent: “method according to claim 36, wherein the total dose of cladribine reached at the end of the induction period is about 1.7 mg/kg”	106
4.	Dependent Claim 41 of the ’947 Patent: “method according to claim 36, wherein the cladribine-free period (ii) lasts about 10 months” ...	107
5.	Dependent Claim 42 of the ’947 Patent: “method according to claim 36, wherein the cladribine-free (iv) period lasts 10 months”	107
6.	Dependent Claim 43 of the ’947 Patent: “method according to claim 36, wherein the maintenance period lasts about 2 months”	108

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.